Class: Local anesthetic
- Injection 2%
- Injection 3%
- Injection 1%
- Injection 2%
- Injection 2%
- Injection 3%
Stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Crosses the placenta by passive diffusion; distributed to some extent to all body systems, with high concentrations found in highly perfused organs, such as the liver, lungs, heart, and brain.
Rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase.
Excreted by the kidney. The plasma half-life in adults is approximately 21 sec for men and 25 sec for women.
6 to 12 min.
Up to 60 min.
Special PopulationsRenal Function Impairment
Pharmacokinetic parameters can be significantly altered.Hepatic Function Impairment
Pharmacokinetic parameters can be significantly altered.Elderly
Pharmacokinetic parameters can be significantly altered.Children
The plasma half-life in neonates is approximately 43 sec.
Indications and Usage
Production of local anesthesia by infiltration and peripheral nerve block.
Hypersensitivity to drugs of the PABA ester group.
Dosage and AdministrationCaudal Block
IV 15 to 25 mL of chloroprocaine 2% or 3% solution without preservatives. Repeated doses may be given at 40- to 60-min intervals.Infiltration and Peripheral Nerve Block
Adults Brachial plexus
IV 30 to 40 mL (600 to 800 mg) as chloroprocaine 2% solution with or without preservatives.Digital
IV 3 to 4 mL (30 to 40 mg) as chloroprocaine 1% solution with or without preservatives (without epinephrine).Infraorbital
IV 0.5 to 1 mL (10 to 20 mg) as chloroprocaine 2% solution with or without preservative.Mandibular
IV 2 to 3 mL (40 to 60 mg) as chloroprocaine 2% solution with or without preservatives.Paracervical
IV 3 mL per each of 4 sites as chloroprocaine 1% solution without preservatives; total dose, up to 120 mg.Pudendal
IV 10 mL, 1 each side as chloroprocaine 2% solution with or without preservative; total dose, 400 mg.Children Infiltration
IV Use concentrations of 0.5% to 1%.Nerve block
IV Use concentrations of 1% to 1.5%.Lumbar Epidural Block
IV 2 to 2.5 mL per segment of chloroprocaine 2% or 3% solution without preservatives. The usual total volume is from 15 to 25 mL. Repeated doses 2 to 6 mL less than the original dose may be given at 40- to 50-min intervals.Elderly
Reduce dosage for elderly.Hepatic Function Impairment
Reduce dosage for patients with liver disease.Special Risk Patients
Reduce dosage in cardiac, debilitated, and acutely ill patients.
- Administer as a single injection or continuously through an indwelling catheter. Do not use for subarachnoid administration.
- Avoid rapid injection; use fractional doses when feasible.
- In adults, max single dose without epinephrine is 11 mg/kg, not to exceed a max total dose of 800 mg. Max single dose with epinephrine is 14 mg/kg, not to exceed a max total dose of 1,000 mg.
- In children, max dose is 11 mg/kg (without epinephrine) determined by the child's age and body weight. This max dose is for children who have a healthy lean body mass and healthy body weight.
- Use an adequate test dose (3 mL of chloroprocaine 3% without preservatives or 5 mL of chloroprocaine 2% without preservatives) prior to induction of complete block. Repeat this test dose if the patient is moved in such a fashion as to have displaced the epidural catheter. Allow adequate time for onset of anesthesia following administration of each test dose.
- To prepare a 1:200,000 epinephrine-chloroprocaine injection, add 0.1 mL of 1:1,000 epinephrine to 20 mL of chloroprocaine without preservatives.
- Chloroprocaine is incompatible with caustic alkalis and their carbonates, soaps, silver salts, and iodides.
- Do not administer if particulate matter, cloudiness, or discoloration noted.
- To avoid intravascular administration, aspirate injection site before anesthetic solution is injected.
- Do not use anesthetic solutions containing preservatives for lumbar or caudal anesthesia.
Store at 68° to 77°F. Keep from freezing and protect from light. Discard unused chloroprocaine without preservatives remaining in vial.
Drug InteractionsErgot-type oxytocics
Do not use vasopressors in the presence of ergot-type oxytocic drugs because severe, persistent hypertension or cerebrovascular accidents may occur.Sulfonamides
The PABA metabolite of chloroprocaine inhibits the action of sulfonamides; do not coadminister.
Laboratory Test Interactions
None well documented.
Bradycardia, cardiac arrest, hypotension, myocardium depression, ventricular arrhythmias.
Anxiety, CNS excitement or depression, convulsions, dizziness, drowsiness, headache, restlessness, tremors, unconsciousness.
Blurred vision, tinnitus.
Allergic reactions (characterized by urticaria, pruritus, erythema, angioneurotic edema, tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and possibly, anaphylactoid-type symptomatology), backache, respiratory arrest.
Careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness should be accomplished after each local anesthetic injection.
Category C .
Safety and effectiveness not established in children younger than 3 yr of age.
Exercise caution in dose selection, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Special Risk Patients
Use with caution in areas of the body supplied by end arteries or having compromised blood supply, and in patients with neurological disease, spinal deformities, septicemia, severe hypertension, impaired CV function, hypotension, heart block, or hepatic disease.
Mixing local anesthetics
Exercise caution regarding toxic equivalence when mixtures of local anesthetics are employed.
When using for retrobulbar block, do not rely upon lack of corneal sensation to determine wether or not the patient is ready for surgery.
Peripheral or hypertensive vascular disease
May exhibit exaggerated vasoconstrictor response, and ischemic injury or necrosis may result.
None well documented.
- Advise patient that medication will be prepared and administered by a health care provider in a medical setting.
- Caution patient that temporary loss of sensation and motor activity may be experienced.
- Instruct patient to inform health care provider if any of the following are experienced during or after the anesthetic injection: anxiety, blurred vision, dizziness, drowsiness or change in mental status, hot or cold sensations, rapid breathing or feeling of shortness of breath, rapid heart rate, restlessness, ringing in the ears.
Copyright © 2009 Wolters Kluwer Health.